Semaglutide clinical trials
Also written Ozempic, Wegovy, NN9535 and NN9924.
Its developmentBy 11 companies, company by company163 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.ClinicalTrials.gov finds 808 studies for Semaglutide. How that becomes 451 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives Semaglutide. Its counts are asked again every night. How drug pages count
- 808Found by its intervention search · See all 808 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 653 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −14
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)NCT01511393 · A thyroid cancer registry; the drug is only a keywordReport a problem
- A Study Comparing the Dulaglutide Pen and the Semaglutide PenNCT03724981 · Pens tried on a practice pad; no drug is givenReport a problem
- SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes TrialNCT04972721 · Follow-up survey of SELECT; no treatment is givenReport a problem
- Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)NCT06221696 · Earlier treatment; a fibre supplement is tested after itReport a problem
- A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · Earlier treatment; orforglipron is tested after itReport a problem
- A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)NCT06605703 · Earlier treatment; the study tests what follows stopping itReport a problem
- Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 AgonistsNCT06640972 · Earlier treatment; RDX-002 is tested after stopping itReport a problem
- MAINTAIN (Mucosal AblatIoN Therapy After INcretins)NCT06734312 · Earlier treatment; a procedure is tested after stopping itReport a problem
- A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 · Only a matching placebo; cagrilintide versions are comparedReport a problem
- Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist TherapyNCT07728669 · Only a keyword; a digital diet tool is testedReport a problem
- A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504 · Only a matching placebo; cagrilintide presentations are comparedReport a problem
- A Retrospective Real-World Cohort StudyNCT07781371 · An epidemiology atlas; no treatment is givenReport a problem
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900 · Earlier treatment; survodutide is started after itReport a problem
- 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 ReceptorNCT07929233 · Participants already take a GLP-1 drug; fasting before endoscopy is comparedReport a problem
- 794Give Semaglutide to participants
- −148Observe patients on it, or give it outside a trial
- −72Compare another treatment with it
- −123Give it beside what is tested
- 451Test it: the count on this site
Get an email when these change. Save the Semaglutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 Dec 2017 · OZEMPIC · NDA 209637 (FDA, Drugs@FDA)
- European Union
- 8 Feb 2018 · Ozempic · EMEA/H/C/004174 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Studies by the year they started
440 studies that test it; most in 2026 (80); 11 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 8 |
| 2014 | 19 |
| 2015 | 3 |
| 2016 | 12 |
| 2017 | 11 |
| 2018 | 13 |
| 2019 | 31 |
| 2020 | 11 |
| 2021 | 32 |
| 2022 | 49 |
| 2023 | 47 |
| 2024 | 57 |
| 2025 | 56 |
| 2026 | 80 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 175 · Other 276
Novo Nordisk A/S (153) · University of Colorado, Denver (8) · Yale University (6) · Mayo Clinic (5) · University Medical Centre Ljubljana (5) · General Committee of Teaching Hospitals and Institutes, Egypt (5) · University Health Network, Toronto (4) · Vanderbilt University Medical Center (4)
Often tested with
Tested in the same studies.
Tirzepatide (23) · Dapagliflozin (9) · Empagliflozin (9) · GLP-1 Mimetic (5) · GLP-1 receptor agonists (5) · Finerenone (5) · Metformin (4) · Liraglutide (4)
Related medicines
As reviewed, each with the page that says it.
- One of GLP-1 receptor agonists source
- One of GLP-1 Mimetic source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 21 phase 3 studies under way
Semaglutide is the comparator. A study of two new drugs counts under both.
- 4Zenagamtide · Novo Nordisk A/S · next primary completion Jul 2028
- 3Bofanglutide · Carnot Laboratories, Gan & Lee Pharmaceuticals. · next primary completion Jun 2027
- 2BGM0504 · BrightGene Bio-Medical Technology Co., Ltd. · next primary completion Apr 2027
- 2Ribupatide · Kailera, Fujian Shengdi Pharmaceutical Co., Ltd. · next primary completion Mar 2027
- 1Retatrutide · Eli Lilly and Company
- 1Mazdutide · Innovent Biologics (Suzhou) Co. Ltd. · next primary completion Dec 2026
- 1Cagrilintide · Novo Nordisk A/S · next primary completion Jun 2028
- 1Bilpatide · Guangdong Raynovent Biotech Co., Ltd · next primary completion Dec 2026
New treatments tested with it · 8 most studied
New when their studies opened, with Semaglutide beside them; studies of each.
Reaching primary completion within a year · 63, 7 in phase 3
Studies that test Semaglutide, phase 3 first.
- Dec 2026Semaglutide for Smoking Cessation in Patients With DiabetesPhase 3 · Ottawa Heart Institute Research Corporation
- Jan 2027A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesPhase 3 · McGill University Health Centre/Research Institute of the McGill University Health Centre
- Jan 2027Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous SemaglutidePhase 2/3 · McGill University Health Centre/Research Institute of the McGill University Health Centre
- Apr 2027Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter SyndromePhase 3 · Georgios Papadakis
- Jul 2027Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled TrialPhase 3 · RenJi Hospital
- Oct 2027Type 1 Diabetes Impacts of Semaglutide on Cardiovascular OutcomesPhase 3 · University of Colorado, Denver
- Nov 2027A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesPhase 3 · Novo Nordisk A/S
- Nov 2026Tirzepatide Impact Assessment StudyNot applicable · Texas Tech University
- Nov 2026Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudyPhase 4 · Steno Diabetes Center Copenhagen
- Dec 2026Semaglutide vs SitagliptinPhase 4 · University Health Network, Toronto
Studies
Open first, then newest update. How each study uses Semaglutide has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 451
- Semaglutide Effects on Sperm Concentration in Overweight Infertile MenNot yet recruitingPhase 2Copenhagen University Hospital at HerlevNCT07946796Written as Semaglutide (Wegovy®)How we knowReport a problem
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionRecruitingPhase 4University of Texas Southwestern Medical CenterNCT07361874Adrenalectomy against semaglutide in cortisol secretionWritten as Intervention 2: SemaglutideHow we knowReport a problem
- GLP-1R Agonist Treatment for Opioid Use DisorderRecruitingPhase 2Milton S. Hershey Medical CenterNCT06548490Semaglutide against sham for opioid use disorderWritten as Semaglutide Pen InjectorHow we knowReport a problem
- A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightRecruitingPhase 1Novo Nordisk A/SNCT07845578High-dose semaglutide on gastric emptyingWritten as SemaglutideHow we knowReport a problem
- GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerRecruitingEarly Phase 1University of ArizonaNCT07627191Semaglutide added to first-line cancer treatmentWritten as GLP1-RA (semaglutide)How we knowReport a problem
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyRecruitingPhase 1/2Vanderbilt University Medical CenterNCT07642635Semaglutide against placebo in Duchenne muscular dystrophyWritten as Semaglutide (Rybelsus®)How we knowReport a problem
- The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced DiabetesRecruitingNot applicableImperial College LondonNCT06318442Semaglutide against metformin in steroid-induced diabetesWritten as Semaglutide Oral ProductHow we knowReport a problem
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.RecruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT07391267Oral semaglutide added to standard care in liver and kidney diseaseWritten as Semaglutide Oral TabletHow we knowReport a problem
- Semaglutide in Youth With Autism Spectrum DisorderRecruitingPhase 4Children's Hospital Medical Center, CincinnatiNCT07770152Semaglutide with lifestyle in autistic youthHow we knowReport a problem
- Validation & Intervention Testing for Aging, Longevity and HealthspanNot yet recruitingPhase 2The University of Texas Health Science Center at San AntonioNCT07923630Oral semaglutide for healthy aging, with dapagliflozin and placebo armsHow we knowReport a problem
- Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseRecruitingPhase 1/2The Methodist Hospital Research InstituteNCT07651319Added to low-dose IL-2 in Alzheimer's diseaseWritten as Semaglutide Plus IL-2How we knowReport a problem
- Semaglutide for the Prevention Of Post-Transplant Diabetes MellitusNot yet recruitingPhase 2/3University Health Network, TorontoNCT06913023Single-arm semaglutide to prevent post-transplant diabetesWritten as Semaglutide 0.25 mgHow we knowReport a problem
- Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthRecruitingPhase 2/3University of Colorado, DenverNCT06975111One of the preventive treatments offered in midlifeWritten as semaglutideHow we knowReport a problem
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use OutcomesRecruitingPhase 1Yale UniversityNCT07772960Two doses against placebo in alcohol use and obesityWritten as Semaglutide 1.0 mgHow we knowReport a problem
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNot yet recruitingPhase 4Jing LuoNCT07832084Tapering against maintenance or other medicinesHow we knowReport a problem
- Semaglutide for Weight Management During Hormone Therapy for Early Breast CancerNot yet recruitingPhase 2Aarhus University HospitalNCT07909889For weight loss during hormone therapy for early breast cancerWritten as Semaglutide (Wegovy®)How we knowReport a problem
- FutureShape FamilyRecruitingPhase 4Signe TorekovNCT07872904Semaglutide against placebo within family careWritten as Semaglutide (administered by PDS290 pen-injector)How we knowReport a problem
- Mechanisms of Weight Loss: Tirzepatide vs SemaglutideRecruitingPhase 4McMaster UniversityNCT07900074Semaglutide and tirzepatide on energy balanceWritten as SemaglutideHow we knowReport a problem
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in ChinaRecruitingPhase 4Novo Nordisk A/SNCT07900438Single-arm semaglutide on kidney and heart outcomesWritten as SemaglutideHow we knowReport a problem
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)RecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT03884075Its effect in fatty liver diseaseWritten as SemaglutideHow we knowReport a problem
See all 451 studies that test Semaglutide →
Behind its US label · 9 — the studies the FDA label of OZEMPIC, WEGOVY describes
From the Clinical Studies section of OZEMPIC (2026-07), WEGOVY (2026-06), as openFDA has it. A study the site does not hold is left out.
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT01720446How we knowReport a problem
- Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT01885208How we knowReport a problem
- Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT01930188How we knowReport a problem
- Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT02054897How we knowReport a problem
- Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT02128932How we knowReport a problem
- Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT02305381How we knowReport a problem
- A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseCompletedPhase 3Novo Nordisk A/SNCT03819153How we knowReport a problem
- A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT03989232How we knowReport a problem
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityCompletedPhase 3Novo Nordisk A/SNCT03574597How we knowReport a problem
Tested on its own · 289 — no other medicine in its arm
- Semaglutide Effects on Sperm Concentration in Overweight Infertile MenNot yet recruitingPhase 2Copenhagen University Hospital at HerlevNCT07946796Written as Semaglutide (Wegovy®)How we knowReport a problem
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionRecruitingPhase 4University of Texas Southwestern Medical CenterNCT07361874Adrenalectomy against semaglutide in cortisol secretionWritten as Intervention 2: SemaglutideHow we knowReport a problem
- GLP-1R Agonist Treatment for Opioid Use DisorderRecruitingPhase 2Milton S. Hershey Medical CenterNCT06548490Semaglutide against sham for opioid use disorderWritten as Semaglutide Pen InjectorHow we knowReport a problem
- GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerRecruitingEarly Phase 1University of ArizonaNCT07627191Semaglutide added to first-line cancer treatmentWritten as GLP1-RA (semaglutide)How we knowReport a problem
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyRecruitingPhase 1/2Vanderbilt University Medical CenterNCT07642635Semaglutide against placebo in Duchenne muscular dystrophyWritten as Semaglutide (Rybelsus®)How we knowReport a problem
- The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced DiabetesRecruitingNot applicableImperial College LondonNCT06318442Semaglutide against metformin in steroid-induced diabetesWritten as Semaglutide Oral ProductHow we knowReport a problem
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.RecruitingNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT07391267Oral semaglutide added to standard care in liver and kidney diseaseWritten as Semaglutide Oral TabletHow we knowReport a problem
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use OutcomesRecruitingPhase 1Yale UniversityNCT07772960Two doses against placebo in alcohol use and obesityWritten as Semaglutide 1.0 mgHow we knowReport a problem
- Semaglutide for Weight Management During Hormone Therapy for Early Breast CancerNot yet recruitingPhase 2Aarhus University HospitalNCT07909889For weight loss during hormone therapy for early breast cancerWritten as Semaglutide (Wegovy®)How we knowReport a problem
- FutureShape FamilyRecruitingPhase 4Signe TorekovNCT07872904Semaglutide against placebo within family careWritten as Semaglutide (administered by PDS290 pen-injector)How we knowReport a problem
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in ChinaRecruitingPhase 4Novo Nordisk A/SNCT07900438Single-arm semaglutide on kidney and heart outcomesWritten as SemaglutideHow we knowReport a problem
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)RecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT03884075Its effect in fatty liver diseaseWritten as SemaglutideHow we knowReport a problem
- Translational Health Research Into Vascular and Neurocognitive Effects of Weight LossRecruitingPhase 4Alain DagherNCT07592546Semaglutide for weight loss, measured on the brainWritten as semaglutideHow we knowReport a problem
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.RecruitingPhase 2/3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT07891156Semaglutide against placebo on body composition in type 1 diabetesWritten as SemaglutideHow we knowReport a problem
- Semaglutide for the Treatment of Cannabis Use DisorderNot yet recruitingPhase 2Massachusetts General HospitalNCT07879612Single-arm semaglutide in cannabis use disorderWritten as semaglutideHow we knowReport a problem
- Short Term Effects of Semaglutide on Body Composition and PerformanceNot yet recruitingNot applicableMorten Hostrup, PhDNCT07874971Semaglutide against placebo on muscleWritten as Semaglutide (SEMA)How we knowReport a problem
- Long-Term Effects of Semaglutide on Body Composition and Performance in RunningNot yet recruitingNot applicableMorten Hostrup, PhDNCT07874932Semaglutide against placebo on muscleWritten as Semaglutide (SEMA)How we knowReport a problem
- Semaglutide for Helping Opioid RecoveryRecruitingPhase 2Brigham and Women's HospitalNCT06639464Semaglutide against placebo for opioid use disorderWritten as SemaglutideHow we knowReport a problem
- Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNot yet recruitingPhase 4General Committee of Teaching Hospitals and Institutes, EgyptNCT07859189Immediate against triggered semaglutide after surgeryWritten as Semaglutide weekly injectionHow we knowReport a problem
- Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNot yet recruitingPhase 4General Committee of Teaching Hospitals and Institutes, EgyptNCT07859176Tapered against abrupt stoppingWritten as Semaglutide weekly injectionHow we knowReport a problem
Showing 20 of 289. See all 289 →
Tested with established drugs · 46 — they are given beside it
- A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightRecruitingPhase 1Novo Nordisk A/SNCT07845578High-dose semaglutide on gastric emptyingWritten as SemaglutideHow we knowReport a problem
- Semaglutide for the Prevention Of Post-Transplant Diabetes MellitusNot yet recruitingPhase 2/3University Health Network, TorontoNCT06913023Single-arm semaglutide to prevent post-transplant diabetesWritten as Semaglutide 0.25 mgHow we knowReport a problem
- Semaglutide for Post-Smoking Cessation Weight ManagementRecruitingPhase 2The University of Texas Health Science Center, HoustonNCT06173778Semaglutide against placebo after smoking cessationWritten as semaglutide 2.4mgHow we knowReport a problem
- Semaglutide for Smoking Cessation in Patients With DiabetesRecruitingPhase 3Ottawa Heart Institute Research CorporationNCT07059377Semaglutide added to nicotine replacement for quittingWritten as SemaglutideHow we knowReport a problem
- Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic SyndromeNot yet recruitingPhase 3All India Institute of Medical Sciences, BhubaneswarNCT07770282Semaglutide against placebo in schizophreniaWritten as Semaglutide + TAUHow we knowReport a problem
- Myocardial Metabolic Flux in Pulmonary Arterial HypertensionNot yet recruitingPhase 2Imperial College LondonNCT07737522Its effect on heart metabolism in pulmonary hypertensionHow we knowReport a problem
- GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized TrialNot yet recruitingPhase 2Chinese University of Hong KongNCT07613437Semaglutide against standard care in brain haemorrhageWritten as Semaglutide, 0.5 mg/mLHow we knowReport a problem
- Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes PatientsRecruitingPhase 3Ole Lander SvendsenNCT07581145Semaglutide against placebo on foot ulcersWritten as Semaglutide, 1.34 mg/mLHow we knowReport a problem
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DMRecruitingPhase 4Federico II UniversityNCT07314684Semaglutide added to standard therapy on inflammationWritten as semaglutideHow we knowReport a problem
- Improved Treatment and Monitoring of Alzheimer's DiseaseNot yet recruitingPhase 2Rune Skovgaard RasmussenNCT07135245Oral semaglutide alone or combined in Alzheimer'sWritten as Semaglutide (Rybelsus®) combined with other interventionsHow we knowReport a problem
- Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and NephropathyNot yet recruitingNot applicableBispebjerg HospitalNCT06555146Its effect on renal blood flowWritten as Semaglutide, 0.5 mg/mLHow we knowReport a problem
- Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension TreatmentNot yet recruitingPhase 3Capital Medical UniversityNCT06361823Semaglutide in intracranial hypertensionWritten as SemaglutideHow we knowReport a problem
- Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 DiabetesNot yet recruitingPhase 3Chengdu Brilliant Pharmaceutical Co., Ltd.NCT06339086A biosimilar semaglutide against OzempicWritten as Semaglutide InjectionHow we knowReport a problem
- Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary SyndromeRecruitingPhase 4Peking University First HospitalNCT05702905Semaglutide against metformin in infertile women with PCOSWritten as Semaglutide, 1.34 mg/mLHow we knowReport a problem
- Semaglutide 2.4mg for Low Responders After Bariatric SurgeryNot yet recruitingPhase 4Zuyderland Medisch CentrumNCT06287307Semaglutide against placebo after poor bariatric responseWritten as Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]How we knowReport a problem
- Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 DiabetesRecruitingPhase 4Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT05597202Its effect on vascular inflammationWritten as Semaglutide, 2.0 mg/mLHow we knowReport a problem
- Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 DiabetesRecruitingPhase 4Kirsi PietiläinenNCT04854083Semaglutide as an adjunct to dietingWritten as Semaglutide, 1.34 mg/mLHow we knowReport a problem
- The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical TrialActive, not recruitingPhase 2Odense University HospitalNCT06050577Oral semaglutide's effect on bone turnoverWritten as oral Semaglutide/RybelsusHow we knowReport a problem
- DUTCH Weight Control in Atrial Fibrillation StudyActive, not recruitingPhase 4Rijnstate HospitalNCT06184633Semaglutide against placebo for rhythm control in atrial fibrillationWritten as Semaglutide 3.2 MG/MLHow we knowReport a problem
- Semaglutide Treatment, Appetite, and Eating Behavior: Long-term EffectsCompletedPhase 4University of PennsylvaniaNCT05548647Semaglutide 2.4 mg's effect on appetite and eatingWritten as Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]How we knowReport a problem
Showing 20 of 46. See all 46 →
Tested in a combination · 116 — another drug in the study is under test too
- Semaglutide in Youth With Autism Spectrum DisorderRecruitingPhase 4Children's Hospital Medical Center, CincinnatiNCT07770152Semaglutide with lifestyle in autistic youthHow we knowReport a problem
- Validation & Intervention Testing for Aging, Longevity and HealthspanNot yet recruitingPhase 2The University of Texas Health Science Center at San AntonioNCT07923630Oral semaglutide for healthy aging, with dapagliflozin and placebo armsHow we knowReport a problem
- Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseRecruitingPhase 1/2The Methodist Hospital Research InstituteNCT07651319Added to low-dose IL-2 in Alzheimer's diseaseWritten as Semaglutide Plus IL-2How we knowReport a problem
- Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthRecruitingPhase 2/3University of Colorado, DenverNCT06975111One of the preventive treatments offered in midlifeWritten as semaglutideHow we knowReport a problem
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNot yet recruitingPhase 4Jing LuoNCT07832084Tapering against maintenance or other medicinesHow we knowReport a problem
- Mechanisms of Weight Loss: Tirzepatide vs SemaglutideRecruitingPhase 4McMaster UniversityNCT07900074Semaglutide and tirzepatide on energy balanceWritten as SemaglutideHow we knowReport a problem
- Impact GLP-1 Agonists Following BariatricRecruitingPhase 4University of Missouri-ColumbiaNCT06132477Continuing GLP-1 agonists after bariatric surgery, semaglutide an optionHow we knowReport a problem
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaRecruitingPhase 2University of FloridaNCT07107334GLP-1 agonist with an LNG-IUD, semaglutide an optionHow we knowReport a problem
- Dietary, Medication, and Endoscopic Interventions for Post-Bariatric HypoglycemiaNot yet recruitingNot applicableStanford UniversityNCT07878494GLP-1 therapy for post-bariatric hypoglycaemiaHow we knowReport a problem
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878One of four kidney drugs started togetherWritten as SemaglutideHow we knowReport a problem
- Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumRecruitingPhase 2GynOncTrialsNCT06073184Semaglutide with a progestin IUD in endometrial diseaseWritten as WegovyHow we knowReport a problem
- The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectRecruitingPhase 3The George InstituteNCT06058585A platform arm of semaglutide against placebo in kidney diseaseWritten as SemaglutideHow we knowReport a problem
- Combination Therapy for Alcohol Use DisorderNot yet recruitingPhase 2Johns Hopkins UniversityNCT07249554Semaglutide with naltrexone against placebo for alcohol useHow we knowReport a problem
- Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"RecruitingPhase 3Centre Hospitalier Universitaire DijonNCT05305794Semaglutide added to insulin in double diabetesHow we knowReport a problem
- A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or ObesityNot yet recruitingPhase 4Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07783854Dose tapering against staying on the maintenance doseHow we knowReport a problem
- Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes MellitusRecruitingPhase 1/2Mapi Pharma Ltd.NCT07563699Dose escalation of a semaglutide depotHow we knowReport a problem
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialRecruitingPhase 2City of Hope Medical CenterNCT07202247Semaglutide or tirzepatide against a healthy diet during androgen deprivationWritten as SemaglutideHow we knowReport a problem
- GLP-1s in Hip and Knee ArthroplastyNot yet recruitingPhase 4Nova Scotia Health AuthorityNCT07755085Semaglutide before joint replacement against placeboHow we knowReport a problem
- Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese ParticipantsRecruitingPhase 1Terrestrial Bio, Inc.NCT07673900A semaglutide microneedle patch against the injectionWritten as semaglutide SCHow we knowReport a problem
- Tirzepatide Impact Assessment StudyRecruitingNot applicableTexas Tech UniversityNCT07740291GLP-1 therapy against lifestyle, semaglutide an optionHow we knowReport a problem
Showing 20 of 116. See all 116 →
Beside an established treatment under test · 6 — an approved drug, surgery or radiation is what the study tests
Tested with Semaglutide: Tirzepatide 1 · Probenecid 1 · Cyclosporine 1 · finerenone 1 · Metformin 1 · Sirolimus 1 · Naltrexone 1 · pramlintide 1
- Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaNot yet recruitingNot applicablePeking University People's HospitalNCT07849348In every armFinerenone is added to semaglutide in every armWritten as SemaglutideHow we knowReport a problem
- Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-CessationRecruitingPhase 2/3AgelessRxNCT07092618In every armOther drugs are tested while semaglutide is taperedHow we knowReport a problem
- Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 DiabetesRecruitingPhase 4Per Løgstrup PoulsenNCT05700877Mandatory in the treatment strategy under testHow we knowReport a problem
- A Study of a Weight Loss Intervention in People With Endometrial CancerActive, not recruitingEarly Phase 1Memorial Sloan Kettering Cancer CenterNCT06751589In every armMay replace tirzepatide, which is what is testedHow we knowReport a problem
- Tailoring Obesity Treatment TrialWithdrawnPhase 2/3Esbjerg Hospital - University Hospital of Southern DenmarkNCT06619015In every armPramlintide is added to semaglutideWritten as Semaglutide Pen InjectorHow we knowReport a problem
- A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy SubjectsCompletedPhase 1Novo Nordisk A/SNCT03466567In every armGiven so drugs' effect on its absorption enhancer can be measuredWritten as SemaglutideHow we knowReport a problem
Beside a new treatment under test · 75 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Semaglutide: cagrilintide 30 · NNC0480-0389 3 · ostarine 2 · zalfermin 2 · linafexor 2 · insulin icodec 2 · AT673 1 · CS060380 1
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideRecruitingPhase 2Eli Lilly and CompanyNCT06897475LY3457263 is added to stable semaglutide or tirzepatideHow we knowReport a problem
- Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsRecruitingPhase 1Shanghai JMT-Bio Inc.NCT07840729JMT206 is tested with semaglutideWritten as Semaglutide injectionHow we knowReport a problem
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyRecruitingPhase 2Biomea Fusion Inc.NCT07502508Icovamenib is tested on an Ozempic-based regimenHow we knowReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesRecruitingPhase 3Novo Nordisk A/SNCT07282613In every armPartner of the new drug in CagriSemaHow we knowReport a problem
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07855133In every armPatients switch from semaglutide to zenagamtideWritten as SemaglutideHow we knowReport a problem
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightRecruitingPhase 3Novo Nordisk A/SNCT07253285In CagriSema, and alone for comparison, in childrenWritten as SemaglutideHow we knowReport a problem
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07564414Partner in CagriSema, and alone in the other armWritten as SemaglutideHow we knowReport a problem
- Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaRecruitingPhase 3Novo Nordisk A/SNCT07817251In every armPatients switch from semaglutide to CagriSemaHow we knowReport a problem
- Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese AdultsNot yet recruitingPhase 2Lumos PharmaNCT07754045In every armLUM-201 is added to semaglutideWritten as SemagludtideHow we knowReport a problem
- Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 DiabetesNot yet recruitingNot applicableEighth Affiliated Hospital, Sun Yat-sen UniversityNCT07599046In every armFaecal transplant is added to semaglutideWritten as Semaglutide (1 Mg Dose)How we knowReport a problem
- Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)RecruitingPhase 1Novo Nordisk A/SNCT07527195Partner in CagriSema, and alone for comparisonWritten as SemaglutideHow we knowReport a problem
- Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DMNot yet recruitingNot applicableShanghai Jiao Tong University School of MedicineNCT07570810In every armCS0159 is tested with semaglutide in every armWritten as SemaglutideHow we knowReport a problem
- A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)RecruitingPhase 2Actimed Therapeutics LtdNCT07101939In every armA new drug is tested to protect muscle on semaglutideWritten as SemaglutideHow we knowReport a problem
- Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.Not yet recruitingPhase 2BiophytisNCT07411378In every armBIO101 is tested in patients on semaglutideWritten as SemaglutideHow we knowReport a problem
- PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese AdultsNot yet recruitingPhase 4Shanghai Zhongshan HospitalNCT06863363In every armPEG-rhGH is added to semaglutide in every armWritten as PEG-rhGH Injection + Semaglutide InjectionHow we knowReport a problem
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationCompletedPhase 2Regeneron PharmaceuticalsNCT06299098New antibodies are added to semaglutideWritten as SemaglutideHow we knowReport a problem
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)CompletedPhase 2Rezera (formerly NodThera Limited)NCT07220629NT-0796 is tested as an adjunct to semaglutideHow we knowReport a problem
- Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide TreatmentCompletedEarly Phase 1University Hospital, Gentofte, CopenhagenNCT07171723A ghrelin antagonist is tested in people on semaglutideHow we knowReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorCompletedPhase 3Novo Nordisk A/SNCT06221969Partner in CagriSema, tested against tirzepatideWritten as SemaglutideHow we knowReport a problem
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothCompletedPhase 3Novo Nordisk A/SNCT06534411Partner in CagriSema, tested against tirzepatideWritten as SemaglutideHow we knowReport a problem
Showing 20 of 75. See all 75 →
Beside supportive care · 33 — a supportive treatment or test is studied
- GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardNot yet recruitingPhase 4University of MinnesotaNCT06977438In every armLifestyle dose is varied with semaglutide in every armWritten as SemaglutideHow we knowReport a problem
- Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 DiabetesNot yet recruitingNot applicableGerman Diabetes CenterNCT07926152In every armContinued in both arms; exercise and protein are testedHow we knowReport a problem
- A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating SpectrumRecruitingPhase 4Universitaire Ziekenhuizen KU LeuvenNCT07870538In every armGiven so predictors of response can be testedHow we knowReport a problem
- MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal DiseaseRecruitingNot applicableOelisoa AndriankajaNCT07478653Dental cleaning is tested in children on semaglutideHow we knowReport a problem
- The Evira Study: Additional Support During Obesity TreatmentRecruitingNot applicableKarolinska InstitutetNCT06836284In every armA digital tool is tested beside obesity medicationHow we knowReport a problem
- Free Fatty Acid Effects In Type 2 DiabetesEnrolling by invitationNot applicableUniversity of UlsterNCT07677995Omega-3 is tested with a semaglutide doseWritten as Semaglutide 0.25 mgHow we knowReport a problem
- HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting SemaglutideNot yet recruitingPhase 2Vanderbilt University Medical CenterNCT07760948In every armHMB is tested during standard semaglutide treatmentHow we knowReport a problem
- Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA TreatmentRecruitingNot applicableHospices Civils de LyonNCT07213323In every armProbiotics are tested in people starting GLP-1 drugsHow we knowReport a problem
- Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection FractionRecruitingPhase 4University of VirginiaNCT07178145An MRI method is tested in patients given semaglutideHow we knowReport a problem
- Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)Not yet recruitingNot applicableHallym UniversityNCT07621640In every armGiven so brown fat can be tested as a predictor of responseWritten as Semaglutide (Wegovy®)How we knowReport a problem
- Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With SemaglutideRecruitingNot applicableSheba Medical CenterNCT06497595In every armExercise and nutrition are tested in patients on WegovyHow we knowReport a problem
- Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?Not yet recruitingNot applicableKnut MaiNCT07711548In every armDiets are tested after weight loss on semaglutideHow we knowReport a problem
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With ObesityRecruitingNot applicableWashington University School of MedicineNCT07091500In every armExercise is tested in patients on semaglutideWritten as SemaglutideHow we knowReport a problem
- Rebalancing the Fat Content of the Heart and MusclesRecruitingNot applicableUniversity of AberdeenNCT07065383In every armSupervised training is tested in patients on semaglutideHow we knowReport a problem
- Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1Not yet recruitingPhase 4William Marsh Rice UniversityNCT07554417Diet and exercise are tested in patients on semaglutideWritten as SemaglutideHow we knowReport a problem
- LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide TherapyRecruitingNot applicableDasman Diabetes InstituteNCT06885736Exercise and protein are tested in patients on semaglutideHow we knowReport a problem
- A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseRecruitingPhase 3Vanda PharmaceuticalsNCT07446439Tradipitant is tested against nausea from GLP-1 drugsHow we knowReport a problem
- Protein Supplementation Intervention on Body WeightRecruitingNot applicableChinese Academy of SciencesNCT06989203Protein supplements are tested beside semaglutideWritten as semaglutideHow we knowReport a problem
- A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 DiabetesRecruitingNot applicableQuickSilver ScientificNCT07195994A supplement is tested with and without semaglutideHow we knowReport a problem
- Tailored Exercise Training Study Among Adults With HFpEFRecruitingPhase 2/3University of Texas Southwestern Medical CenterNCT07223242Exercise is tested, with weight-loss medicines among its armsHow we knowReport a problem
Showing 20 of 33. See all 33 →
One option of several · 8 — a test or a strategy chooses among drugs
- Preoperative Weight Loss for Open Abdominal Wall ReconstructionRecruitingNot applicableBenjamin T. MillerNCT05925959One option of a preoperative weight programmeHow we knowReport a problem
- Danish Trial of Weight Loss to Reduce Atrial Fibrillation ProgressionNot yet recruitingNot applicableAxel BrandesNCT07816744One step of a structured weight-loss programmeHow we knowReport a problem
- Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity PharmacotherapyNot yet recruitingNot applicablePhenomix SciencesNCT07728812One option of test-guided obesity treatmentHow we knowReport a problem
- SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial CancerNot yet recruitingPhase 4Hospital Universitari de BellvitgeNCT07462663One part of a pre-surgical strategy under testHow we knowReport a problem
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney DiseaseRecruitingPhase 4Peter RossingNCT07239570One drug of a biomarker-targeted strategyWritten as SemaglutideHow we knowReport a problem
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedPhase 4Fundación para la Investigación del Hospital Clínico de ValenciaNCT06851962In every armOne option of a pharmacogenetic strategy under testWritten as Semaglutide 1.0 mgHow we knowReport a problem
- Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)Active, not recruitingNot applicableFoundation for Atlanta Veterans Education and Research, Inc.NCT05040087One step of a treatment strategy under testHow we knowReport a problem
- Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot StudyTerminatedPhase 2Iain BressendorffNCT05897372In every armOne drug of an albuminuria protocol under testWritten as ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinibHow we knowReport a problem
Given beside what is tested · 2 — usual care or a partner of the new treatment
- Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRINot yet recruitingEarly Phase 1Sunnybrook Health Sciences CentreNCT07820722In every armAn imaging tracer is tested in patients on semaglutideHow we knowReport a problem
- A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After MenopauseCompletedPhase 1Novo Nordisk A/SNCT05153564In every armWith the new drug NNC0480-0389, tested on a contraceptive's kineticsWritten as Semaglutide 1.34 mg/mLHow we knowReport a problem
As the comparator · 72 — what is tested is compared with Semaglutide
- A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or ObesityNot yet recruitingPhase 1Novo Nordisk A/SNCT07940582Written as SemaglutideHow we knowReport a problem
- Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy AdultsNot yet recruitingPhase 1Korea United Pharm. Inc.NCT07935200Wegovy as the reference for UI112, another semaglutide productWritten as Semaglutide (UIC202611)How we knowReport a problem
- A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothNot yet recruitingPhase 3Novo Nordisk A/SNCT07931599Comparator for new zenagamtide at lower dosesWritten as SemaglutideHow we knowReport a problem
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothNot yet recruitingPhase 3Novo Nordisk A/SNCT07931573Comparator for new zenagamtide at higher dosesWritten as SemaglutideHow we knowReport a problem
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07112872Oral semaglutide is the open comparator for new tifeglipronWritten as SemaglutideHow we knowReport a problem
- A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes MellitusNot yet recruitingPhase 2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07923357Open comparator for new SAL0150 tabletsHow we knowReport a problem
- A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityNot yet recruitingPhase 3Novo Nordisk A/SNCT07919405Written as SemaglutideHow we knowReport a problem
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityRecruitingPhase 3PfizerNCT07845500Switching to berobenatide against staying on semaglutideWritten as SemaglutideHow we knowReport a problem
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesRecruitingPhase 3AmgenNCT07866066Maridebart cafraglutide is tested against semaglutideWritten as SemaglutideHow we knowReport a problem
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver DiseaseRecruitingPhase 4The Cleveland ClinicNCT07058155TIPS with surgery against medical care, semaglutide an optionHow we knowReport a problem
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07662213Elecoglipron is tested against oral semaglutideWritten as SemaglutideHow we knowReport a problem
- A Study of BGM0504 in Early T2DM With ObesityRecruitingPhase 3BrightGene Bio-Medical Technology Co., Ltd.NCT07743983BGM0504 is tested against semaglutideWritten as semaglutideHow we knowReport a problem
- A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesRecruitingPhase 2Novo Nordisk A/SNCT07668388UBT251 is dose-found against semaglutideWritten as SemaglutideHow we knowReport a problem
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideRecruitingPhase 3Novo Nordisk A/SNCT07668414Zenagamtide is tested against semaglutideWritten as SemaglutideHow we knowReport a problem
- Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)RecruitingPhase 3The United Bio-Technology (Hengqin) Co., Ltd.NCT07653477UBT251 is tested against semaglutideWritten as Semaglutide InjectionHow we knowReport a problem
- A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesRecruitingPhase 2Novo Nordisk A/SNCT07415954NNC0662-0419 is dose-found against semaglutideWritten as SemaglutideHow we knowReport a problem
- A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)Not yet recruitingPhase 2Beijing QL Biopharmaceutical Co.,LtdNCT07812597Switching to zovaglutide against staying on semaglutideWritten as semaglutideHow we knowReport a problem
- The Role of the Amylin Analogue Cagrilintide in Bone MetabolismRecruitingPhase 1Novo Nordisk A/SNCT07010432Cagrilintide on bone, semaglutide the comparisonWritten as SemaglutideHow we knowReport a problem
- Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes MellitusRecruitingPhase 2Shanghai Minwei Biotechnology Co., LtdNCT07801820MWN109 is tested; oral semaglutide is the active controlWritten as Semaglutide TabletsHow we knowReport a problem
- A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07767175NNC0721-8060 is tested; semaglutide is the active comparatorWritten as SemaglutideHow we knowReport a problem
Showing 20 of 72. See all 72 →
Observed · 148 — patients on it are followed, or it is given outside a trial
- Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)RecruitingNemours Children's ClinicNCT07169136Observes adolescents with PCOS on semaglutideHow we knowReport a problem
- GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort StudyRecruitingNoom Inc.NCT07588984Observes people on semaglutide with a digital programmeWritten as SemaglutideHow we knowReport a problem
- Ocular Changes in Patients Using Tirzepatide or SemaglutideRecruitingIstanbul UniversityNCT07924618Written as SemaglutideHow we knowReport a problem
- Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With ObesityRecruitingYuzuncu Yil UniversityNCT07901777Observes GLP-1 therapy against sleeve gastrectomyHow we knowReport a problem
- Changes in Body Composition Following Pharmacological Treatment for Obesity.Enrolling by invitationHospital San Carlos, MadridNCT07908940Body composition after weight loss on semaglutideHow we knowReport a problem
- Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent ObesityNot yet recruitingErin MauneyNCT07911046Written as SemaglutideHow we knowReport a problem
- A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyNot yet recruitingNovartis PharmaceuticalsNCT07881783Observes secukinumab with concurrent GLP-1 drugsHow we knowReport a problem
- Semaglutide Health Outcomes and Patient Adherence in AustraliaNot yet recruitingNovo Nordisk A/SNCT07881770Observes semaglutide on digital platformsWritten as SemaglutideHow we knowReport a problem
- GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without DiabetesRecruitingIstanbul Saglik Bilimleri UniversityNCT07858864Observes sarcopenia in GLP-1 usersHow we knowReport a problem
- Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKDRecruitingUniversity of AlbertaNCT07187830Observes kidney patients with and without semaglutideHow we knowReport a problem
- Imaging in Semaglutide StudyRecruitingThe Cleveland ClinicNCT07695454Observes muscle in patients prescribed semaglutideHow we knowReport a problem
- WEgovy Real World Assessment of Weight Loss in KoreaEnrolling by invitationNovo Nordisk A/SNCT07280221Non-interventional study of Wegovy in KoreaWritten as SemaglutideHow we knowReport a problem
- NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World StudyNot yet recruitingIstanbul Saglik Bilimleri UniversityNCT07846956Observes optic neuropathy in GLP-1 usersHow we knowReport a problem
- Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNot yet recruitingNovo Nordisk A/SNCT05714683Post-marketing surveillance of RybelsusWritten as SemaglutideHow we knowReport a problem
- Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated ObesityNot yet recruitingNantes University HospitalNCT07423481Follow-up of patients treated with WegovyHow we knowReport a problem
- GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNot yet recruitingMiedziowe Centrum Zdrowia SANCT07787936Observes patients on GLP-1 agonists in heart failureHow we knowReport a problem
- Comparing Facial Aging Between Identical Twins With 3D ImagingNot yet recruitingPonsky Facial Aesthetics And Plastic Surgery, LlcNCT07760532Observes facial ageing in twins, some on GLP-1 drugsHow we knowReport a problem
- A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeEnrolling by invitationNovo Nordisk A/SNCT07055607Real-world study of WegovyWritten as SemaglutideHow we knowReport a problem
- Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsRecruitingOhio State UniversityNCT07702461Survey of people on GLP-1 agonistsHow we knowReport a problem
- Salivary Function and Dental Changes During GLP-1 TherapyNot yet recruitingBilecik Seyh Edebali UniversitesiNCT07720466Observes saliva in patients on semaglutide or tirzepatideHow we knowReport a problem
Showing 20 of 148. See all 148 →
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting7
- A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightNov 17, 2026NCT07845578
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyNov 12, 2026NCT07642635
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.Nov 9, 2026NCT07391267
- Semaglutide in Youth With Autism Spectrum DisorderNov 9, 2026NCT07770152
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use OutcomesNov 4, 2026NCT07772960
Show 2 moreShow fewer
- FutureShape FamilyOct 29, 2026NCT07872904
- Translational Health Research Into Vascular and Neurocognitive Effects of Weight LossOct 26, 2026NCT07592546
Results posted3
- Lifestyle Counseling and Medication for Adolescent Weight ManagementNov 6, 2026NCT04873245
- Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNov 2, 2026NCT04916470
- Semaglutide 2.4 mg in Patients With Poor Weight-lossOct 26, 2026NCT05073835
Newly registered6
- Semaglutide Effects on Sperm Concentration in Overweight Infertile MenNov 18, 2026NCT07946796
- Validation & Intervention Testing for Aging, Longevity and HealthspanNov 6, 2026NCT07923630
- Semaglutide for Weight Management During Hormone Therapy for Early Breast CancerNov 2, 2026NCT07909889
- Mechanisms of Weight Loss: Tirzepatide vs SemaglutideOct 28, 2026NCT07900074
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in ChinaOct 28, 2026NCT07900438
Show 1 moreShow fewer
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.Oct 23, 2026NCT07891156
Codes
What other systems call Semaglutide · ClinicalTrials.gg INT006888
- MeSH (NLM) D000099194SemaglutideConfirmed NLM, Wikidata
- UNII (FDA) 53AXN4NNHXSEMAGLUTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1991302Confirmed FDA, Wikidata
- Wikidata Q27261089semaglutideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152328SemaglutideOne source FDA
- DrugBank DB13928One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000099194 | Semaglutide | Confirmed NLM, Wikidata |
| UNII (FDA) | 53AXN4NNHX | SEMAGLUTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1991302 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27261089 | semaglutide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152328 | Semaglutide | One source FDA |
| DrugBank | DB13928 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.